Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Hizentra is a 20 percent human immune globulin product for subcutaneous infusion. It treats primary immunodeficiency in adults and children age 2 and older and is used as maintenance therapy for chronic inflammatory demyelinating polyneuropathy in adults.
read more about hizentra ...Hizentra supplies a broad range of immunoglobulin G antibodies with opsonizing and neutralizing activity against bacterial and viral agents. Its full mechanism is not completely defined. Immunomodulatory effects also contribute to its activity in chronic inflammatory demyelinating polyneuropathy.
Hizentra is used for primary immunodeficiency in adults and pediatric patients age 2 and older. It is also used for maintenance treatment of chronic inflammatory demyelinating polyneuropathy in adults after stabilization with immune globulin therapy.
Primary immunodeficiency dosing is individualized from the previous immune globulin regimen and can be given weekly, every two weeks, or more frequently. Adult CIDP maintenance commonly uses 0.2 g per kg subcutaneously once weekly and can increase to 0.4 g per kg weekly based on clinical response.
Hizentra carries a boxed warning for thrombosis. Other serious concerns include severe hypersensitivity, aseptic meningitis syndrome, kidney dysfunction, hemolysis, transfusion-related acute lung injury, and transmission of infectious agents from human plasma despite manufacturing safeguards. Hyperprolinemia and selected IgA-related hypersensitivity states are contraindications.
Hizentra treats primary immunodeficiency from age 2 and adult chronic inflammatory demyelinating polyneuropathy maintenance.
Hizentra is infused into subcutaneous tissue using a prescribed infusion schedule and trained administration technique.
A common starting maintenance dose is 0.2 g per kg once weekly, with an increase to 0.4 g per kg weekly when clinically needed.
Yes. The boxed warning concerns thrombosis associated with immune globulin treatment.
DailyMed - HIZENTRA (human immunoglobulin G) liquid. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b58f5ff-0316-49a3-b585-1f6003ddb953. Date Accessed October 1, 2026.
HIZENTRA. U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/hizentra. Date Accessed October 1, 2026.
HIZENTRA Prescribing Information. CSL Behring. https://labeling.cslbehring.com/PI/US/Hizentra/EN/Hizentra-Prescribing-Information.pdf. Date Accessed October 1, 2026.
Human Immunoglobulin G. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Human-Immunoglobulin-G. Date Accessed October 1, 2026.
Immune Globulin Subcutaneous (Human). MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a624083.html. Date Accessed October 1, 2026.